Skip to main content

How can we help you?

  • Deal or case news
  • 19-11-2020

NautaDutilh assisted Pharvaris B.V. with its $80 million Series C financing round, bringing its total venture funding to over $160 million to date. NautaDutilh also assisted Pharvaris with its Series B financing in 2019. 

Pharvaris is a clinical-stage company focused on bringing oral bradykinin B2-receptor antagonists to patients. By targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team is advancing new alternatives to injected therapies for all sub-types of hereditary angioedema (HAE) and other bradykinin B2-receptor-mediated indications.

Viking Global Investors and General Atlantic co-led the financing, with participation by Cormorant Asset Management. Current investors Foresite Capital, Bain Capital Life Sciences, venBio Partners and Venrock Healthcare Capital Partners also participated in the round.

Cookie notice

We care about your privacy. We only use cookies strictly necessary to ensure the proper functioning of our website. You can find more information on cookies and on how we handle your personal data in our Privacy and Cookie Policy.